BeiGene (STU:49B) Accumulated Depreciation : €-244 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

BeiGene's quarterly accumulated depreciation increased from Sep. 2023 (€-207 Mil) to Dec. 2023 (€-229 Mil) and increased from Dec. 2023 (€-229 Mil) to Mar. 2024 (€-244 Mil).

BeiGene's annual accumulated depreciation increased from Dec. 2021 (€-110 Mil) to Dec. 2022 (€-162 Mil) and increased from Dec. 2022 (€-162 Mil) to Dec. 2023 (€-229 Mil).

BeiGene Accumulated Depreciation Historical Data

The historical data trend for BeiGene's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Accumulated Depreciation Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-33.04

-60.30

-109.99

-161.87

-228.53

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-178.49	-185.90	-206.92	-228.53	-243.80

BeiGene Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

BeiGene Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of BeiGene's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (STU:49B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (STU:49B) Headlines

No Headlines